Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against autoimmune diseases
Ronghan Liu, Yuehong Chen, Wenyu Fu, Shuya Wang, Yazhou Cui, Xiangli Zhao, Zi‐Ning Lei, Aubryanna Hettinghouse, Jody Liu, Chao Wang, Chen Zhang, Yufei Bi, Guozhi Xiao, Zhe‐Sheng Chen, C.-J. Liu
This study identifies Fexofenadine as an inhibitor of TNF signaling through targeting cytosolic phospholipase A2, showing therapeutic potential in autoimmune diseases.
Annals of the Rheumatic Diseases · Oct 15, 2019Peer-reviewedMolecular Biology